Results 131 to 140 of about 264,642 (338)
Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma [PDF]
, 2018 Purpose The anti–programmed death-1 antibody pembrolizumab was evaluated in KEYNOTE-028, a multicohort, phase IB study of patients with programmed death ligand-1 (PD-L1)–positive advanced solid tumors.
Bennouna, Jaafar +6 more
core +1 more source
Gland Surgery, 2019 Metastatic cancer continues to be a devastating disease with few effective treatment options. One promising approach that has emerged recently is immunotherapy, and the immune checkpoint protein programmed death-ligand 1 (PD-L1) has garnered particular interest given its role in immune system evasion by cancer cells (1,2).
John M. Lamar, Ryan Kanai
openaire +3 more sources
Probiotic‐Based Materials as Living Therapeutics
Advanced Materials, EarlyView.Recent advances in Engineered Living Materials are highlighted, integrating synthetic biology and advanced materials, with a focus on probiotic‐based therapeutics. Probiotic Living Materials hold great potential for biosensing, infection treatment, osteogenesis, wound healing, vaginal and gastrointestinal disorders, and cancer therapy. breakthroughs in
Laura Sabio +2 more
wiley +1 more source
Characterisation of novel lung cancer cell lines for immuno-inhibitory markers [PDF]
The present study investigates the expression of immune biomarkers, PD-L1 and HLA-1 on novel lung cancer cell lines (H838, H838-EGFR, A549, A549-ALK, HCC 827, NCI 1650, TWIT, Jacket). PD-L1 and HLA-1 characterisation were initially performed and analysed
Cross, Neil +2 more
core
Expression and Regulation of the PD-L1 Immunoinhibitory Molecule on Microvascular Endothelial Cells [PDF]
, 2002 MICHAEL J. EPPIHIMER +6 more
openalex +1 more source
Advanced Materials, EarlyView.A reprogrammed (RP) phage‐based nanovaccine platform has been developed that allows single‐step assembly with precise control over adjuvanticity, antigen density, and nanoparticle size. By enhancing TLR9 activation and neoantigen display, this platform enables a potent personalized vaccine targeting tumor‐specific neoantigens. When combined with immune
Shengnan Huang +10 more
wiley +1 more source
Cell Reports, 2018 Summary: The PD-1 pathway, consisting of the co-inhibitory receptor PD-1 on T cells and its ligand (PD-L1) on antigen-presenting cells (APCs), is a major mechanism of tumor immune evasion.
Yunlong Zhao +5 more
doaj +1 more source
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade [PDF]
, 2002 Yoshiko Iwai +5 more
openalex +1 more source
Factors correlating the expression of PD-L1
BMC CancerAbstract Objective PD-L1 was an important biomarker in lung adenocarcinoma. The study was to confirm the most important factor affecting the expression of PD-L1 remains undetermined. Methods The clinical records of 1045 lung adenocarcinoma patients were retrospectively ...
Fang Lu, Ernuo Wang, Haiquan Liu
openaire +3 more sources
Advanced Materials, EarlyView.This review summarizes recent advances in metal‐based nanomaterials (MBNs) as multifunctional platforms for next‐generation diagnostics and nanodynamic therapies (NDTs), highlighting their structural tunability, diverse therapeutic modalities, and broad biomedical applications in oncology and infectious disease control.
Qihang Ding +11 more
wiley +1 more source